Matthew Sykes
Stock Analyst at Goldman Sachs
(3.72)
# 786
Out of 4,712 analysts
189
Total ratings
51.16%
Success rate
6.27%
Average return
Main Sectors:
Stocks Rated by Matthew Sykes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NAUT Nautilus Biotechnology | Downgrades: Sell | $2.25 → $1.75 | $1.73 | +1.16% | 5 | Dec 5, 2024 | |
| MRVI Maravai LifeSciences Holdings | Downgrades: Sell | $7 → $4.25 | $5.33 | -20.26% | 10 | Dec 5, 2024 | |
| VCYT Veracyte | Downgrades: Neutral | $38 → $37 | $41.18 | -10.15% | 5 | Dec 5, 2024 | |
| BRKR Bruker | Upgrades: Neutral | $60 | $58.25 | +3.00% | 4 | Dec 5, 2024 | |
| GH Guardant Health | Maintains: Buy | $32 → $36 | $31.57 | +14.03% | 11 | Nov 7, 2024 | |
| EXAS Exact Sciences | Maintains: Buy | $75 → $65 | $58.11 | +11.86% | 13 | Nov 6, 2024 | |
| IQV IQVIA Holdings | Maintains: Buy | $280 → $250 | $199.99 | +25.01% | 2 | Nov 1, 2024 | |
| WGS GeneDx Holdings | Maintains: Neutral | $54 → $70 | $77.40 | -9.56% | 10 | Oct 30, 2024 | |
| TXG 10x Genomics | Maintains: Sell | $16 → $14 | $14.67 | -4.57% | 6 | Oct 30, 2024 | |
| ICLR ICON Public Limited Company | Maintains: Buy | $370 → $280 | $213.26 | +31.30% | 2 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $140 | $162.39 | -13.79% | 12 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $35 | $21.42 | +63.40% | 9 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $26 → $23 | $18.75 | +22.67% | 2 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $290 → $250 | $186.29 | +34.20% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $250 | $230.75 | +8.34% | 4 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $55 | $48.90 | +12.47% | 9 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $23 → $6.5 | $19.35 | -66.41% | 11 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $24 | $10.52 | +128.14% | 13 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,150 → $1,300 | $1,246.30 | +4.31% | 7 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $12 | $9.37 | +28.07% | 6 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7 → $2.5 | $1.95 | +28.21% | 3 | Apr 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $550 → $640 | $528.98 | +20.99% | 6 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $10 | $6.49 | +54.08% | 8 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $19 | $17.15 | +10.79% | 5 | Feb 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $31 | $13.74 | +125.62% | 9 | Jan 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $26 | $21.36 | +21.72% | 5 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $128 → $145 | $135.73 | +6.83% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $45.06 | - | 5 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $105 | $112.53 | -6.69% | 1 | Oct 31, 2023 |
Nautilus Biotechnology
Dec 5, 2024
Downgrades: Sell
Price Target: $2.25 → $1.75
Current: $1.73
Upside: +1.16%
Maravai LifeSciences Holdings
Dec 5, 2024
Downgrades: Sell
Price Target: $7 → $4.25
Current: $5.33
Upside: -20.26%
Veracyte
Dec 5, 2024
Downgrades: Neutral
Price Target: $38 → $37
Current: $41.18
Upside: -10.15%
Bruker
Dec 5, 2024
Upgrades: Neutral
Price Target: $60
Current: $58.25
Upside: +3.00%
Guardant Health
Nov 7, 2024
Maintains: Buy
Price Target: $32 → $36
Current: $31.57
Upside: +14.03%
Exact Sciences
Nov 6, 2024
Maintains: Buy
Price Target: $75 → $65
Current: $58.11
Upside: +11.86%
IQVIA Holdings
Nov 1, 2024
Maintains: Buy
Price Target: $280 → $250
Current: $199.99
Upside: +25.01%
GeneDx Holdings
Oct 30, 2024
Maintains: Neutral
Price Target: $54 → $70
Current: $77.40
Upside: -9.56%
10x Genomics
Oct 30, 2024
Maintains: Sell
Price Target: $16 → $14
Current: $14.67
Upside: -4.57%
ICON Public Limited Company
Oct 25, 2024
Maintains: Buy
Price Target: $370 → $280
Current: $213.26
Upside: +31.30%
Oct 16, 2024
Maintains: Buy
Price Target: $125 → $140
Current: $162.39
Upside: -13.79%
Oct 16, 2024
Maintains: Buy
Price Target: $26 → $35
Current: $21.42
Upside: +63.40%
Oct 8, 2024
Maintains: Neutral
Price Target: $26 → $23
Current: $18.75
Upside: +22.67%
Aug 8, 2024
Maintains: Buy
Price Target: $290 → $250
Current: $186.29
Upside: +34.20%
Jul 24, 2024
Maintains: Neutral
Price Target: $225 → $250
Current: $230.75
Upside: +8.34%
Jul 9, 2024
Maintains: Buy
Price Target: $45 → $55
Current: $48.90
Upside: +12.47%
Jul 9, 2024
Maintains: Neutral
Price Target: $23 → $6.5
Current: $19.35
Upside: -66.41%
Jul 9, 2024
Maintains: Buy
Price Target: $35 → $24
Current: $10.52
Upside: +128.14%
Jul 9, 2024
Maintains: Neutral
Price Target: $1,150 → $1,300
Current: $1,246.30
Upside: +4.31%
Jul 9, 2024
Maintains: Sell
Price Target: $32 → $12
Current: $9.37
Upside: +28.07%
Apr 19, 2024
Maintains: Neutral
Price Target: $7 → $2.5
Current: $1.95
Upside: +28.21%
Apr 10, 2024
Maintains: Buy
Price Target: $550 → $640
Current: $528.98
Upside: +20.99%
Feb 29, 2024
Maintains: Buy
Price Target: $9 → $10
Current: $6.49
Upside: +54.08%
Feb 22, 2024
Maintains: Buy
Price Target: $17 → $19
Current: $17.15
Upside: +10.79%
Jan 30, 2024
Maintains: Buy
Price Target: $28 → $31
Current: $13.74
Upside: +125.62%
Dec 7, 2023
Maintains: Buy
Price Target: $23 → $26
Current: $21.36
Upside: +21.72%
Dec 7, 2023
Maintains: Buy
Price Target: $128 → $145
Current: $135.73
Upside: +6.83%
Dec 7, 2023
Upgrades: Buy
Price Target: n/a
Current: $45.06
Upside: -
Oct 31, 2023
Maintains: Buy
Price Target: $120 → $105
Current: $112.53
Upside: -6.69%